The expression level of the enhancer of zeste homolog 2 (EZH2), deleted in liver cancer 1 (DLC1), is negatively correlated in breast cancer, where the upregulation of EZH2 and the downregulation of DLC1 have been reported in breast cancer tissue and MDA-MB-231 cells. Here, EZH2 is linked to breast carcinoma.